From AVAC <[email protected]>
Subject New Issue of PxWire: A look at where we are in HIV prevention
Date July 29, 2022 6:48 PM
  Links have been removed from this email. Learn more in the FAQ.
  Links have been removed from this email. Learn more in the FAQ.
July 29, 2022

PxWire is AVAC's quarterly update covering the latest in the field of biomedical HIV prevention research and development, implementation and advocacy. Each issue includes news, emerging issues and features upcoming events.

The HIV field gathers for its first hybrid International AIDS Conference (IAC) since the start of COVID-19 pandemic at a pivotal moment in HIV prevention. Across research to rollout – accelerated product access, new products reaching the market, new trials starting (and pausing) and recent research results – the ability to deliver two new proven PrEP methods will be determined by conversations and decisions happening now.

After initial approval ten years ago, oral PrEP initiations have surpassed 2M globally, reaching 2,797,304 – with significant progress over the past year, but still well below UN targets.

Visit here to read the full quarterly report: [link removed]

Best,
AVAC

============================================================
Unsubscribe You're receiving this because you signed up for our newsletter. Not interested any longer?
** Unsubscribe

Contact Us T: +1 212 796 6423
E: ** [email protected]
W: ** www.avac.org
** www.twitter.com/hivpxresearch
** www.facebook.com/hivpxresearch
** www.youtube.com/hivpxresearch
==============================================

Unsubscribe [email protected] from this list:
[link removed]
Screenshot of the email generated on import

Message Analysis